Table 5 GEE regression results with interaction of PFOA (top) and PFOS (bottom) and days from first vaccine to explain outcome in log2 anti-S antibody AUC.
Day 0 to day 68 after first vaccinea (initial increase phase) | Day 42 to day 103 after first vaccineb (waning phase) | |||
|---|---|---|---|---|
Percent change (95% CI) | P-value | Percent change (95% CI) | P-value | |
Age | −1.2 (−3.1, 0.8) | 0.24 | −2.7 (−4.1, −1.4) | <0.001 |
Female vs. Male | −15.2 (−56.1, 63.6) | 0.62 | 2.2 (−31.7, 52.6) | 0.92 |
Geographical site | −20.8 (−63.1, 69.9) | 0.55 | −10.1 (−42.2, 39.5) | 0.64 |
History of COVID-19 (naive vs. recovered) | 1860 (924.2, 3650.7) | <0.01 | 47.4 (−0.7, 118.9) | 0.05 |
Vaccine Brand (Moderna vs. Pfizer-BioNTech) | −31.7 (−73.1, 73) | 0.42 | −36.3 (−60.8, 3.5) | 0.07 |
log2 serum PFOA concentration | −0.1 (−48.8, 21.9) | 0.46 | 0.4 (−5, 93) | 0.08 |
Visit 3 vs. baseline | 71218.1 (27765.8, 182427.5) | <0.01 | ||
Visit 3 × log2 serum PFOA concentration | 30.4 (−9.7, 70.5) | 0.14 | ||
Days from first vaccine | −1.4 (−2.7, 0.7) | 0.19 | ||
Days from first vaccine × log2 serum PFOA concentration | −1 (−1, 0.2) | 0.17 | ||
Age | −1.2 (−3.2, 0.7) | 0.22 | −2.7 (−4.1, −1.4) | <0.001 |
Female vs. Male | −15.2 (−55.9, 63) | 0.62 | 1.4 (−32.2, 51.6) | 0.95 |
Geographical site | −21.6 (−60.6, 55.8) | 0.49 | −19.9 (−46.8, 21.4) | 0.3 |
History of COVID-19 (naive vs. recovered) | 1884.8 (934.5, 3708.2) | <0.01 | 47.4 (−0.7, 118.9) | 0.05 |
Vaccine Brand (Moderna vs. Pfizer-BioNTech) | −29.6 (−72.5, 80.1) | 0.46 | −34 (−59.1, 6.4) | 0.09 |
log2 serum PFOS concentration | −0.1 (−42.7, 29.6) | 0.72 | 0.3 (−30, 94) | 0.31 |
Visit 3 vs. baseline | 67965.9 (18340.8, 251135.1) | <0.01 | ||
Visit 3 × log2 serum PFOS concentration | 20.2 (−25.9, 66.4) | 0.39 | ||
Days from first vaccine | −0.7 (−3.4, 1.4) | 0.44 | ||
Days from first vaccine × log2 serum PFOS concentration | −0.3 (−1, 1) | 0.41 | ||
